SEC Form 4 · accession 0000921895-18-000133
Enveric Biosciences, Inc. · ENVB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Brent Kelton
Officer — Chief Executive Officer
Period of report
Dec 26, 2017
Accepted (ET)
Jan 11, 2018 · 6:15 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000890821
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 8,173 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option (Right to Buy)F1 | $3.00 | Dec 26, 2017 | A | 100,000 | A | Dec 26, 2018 | Dec 26, 2022 | Common Stock | 100,000 | 100,000 | D |
Explanation of responses
- F1The Option vests as follows: (a) as to 33,333 shares of common stock of the Issuer ("Stock), on December 26, 2018, (b) as to a further 33,333 shares of Stock, on December 26, 2019, and (c) as to the remaining 33,334 shares of Stock, on December 26, 2020.